With the long-term goal of better understanding the role of cholangiocytes (epithelial cells that line bile ducts) in health and disease, the current proposal focuses on the interactions between biliary epithelia and Cryptosporidium parvum (C. parvum), an emerging pathogen important in the development of AIDS-cholangiopathy. Using an in vitro model of biliary cryptosporidiosis established by the authors, they have found that C. parvum activates the NF-kB system in directly infected cholangiocytes; discovered that C. parvum induces apoptosis only in bystander uninfected cholangiocytes via a Fas/FasL dependent mechanism; and demonstrated that C. parvum induces FasL expression and stimulates membrane FasL cleavage in directly infected cholangiocytes. They have also found that while HIV- 1 can not infect cholangiocytes, recombinant biologically active HIV- 1 TAT protein enhances both Fas-mediated and C. parvum-associated apoptosis in cholangiocytes. Based on these preliminary data, the authors propose the novel central hypothesis that C. parvum induces biliary tract disease in patients with AIDS by two interdependent and complementary mechanisms: (i) C. parvum inhibits apoptosis in infected cholangiocytes by activation of the NF-kB survival pathway allowing the organism to parasitize the infected cell to propagate; (ii) C. parvum promotes apoptosis in uninfected cholangiocytes via activation of the Fas/FasL pro-apoptotic pathway and the synergistic effects of HIV-dependent soluble factors such as TAT. They will employ complementary biochemical, molecular and morphologic approaches to address three specific aims: (1) C. parvum activates the NFkB system via direct parasite/host cell membrane interactions and triggers cell survival signals allowing for microbial propagation; (2) C. parvum activates nuclear transcription factors to induce FasL expression in directly infected cholangiocytes and stimulates membrane FasL cleavage; and (3) upregulation of FasL expression and increase of membrane FasL cleavage in C. parvum infected cholangiocytes, synergistically with HIV-1 TAT protein, causes apoptosis in bystander uninfected cells via a Fas/FasL dependent mechanism. Results of these experiments will clarify the molecular mechanisms by which C. parvum is cytopathic for biliary epithelial cells. Innovative aspects of the program include novel methodologies and concepts regarding C. parvum-cholangiocyte interaction. The information generated could provide a theoretical framework for development of novel therapeutic strategies for C. parvum induced AIDS-cholangiopathy.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
3R01DK057993-05S1
Application #
7168174
Study Section
General Medicine A Subcommittee 2 (GMA)
Program Officer
Hamilton, Frank A
Project Start
2001-04-01
Project End
2007-02-28
Budget Start
2006-03-01
Budget End
2007-02-28
Support Year
5
Fiscal Year
2006
Total Cost
$147,264
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Guicciardi, Maria Eugenia; Trussoni, Christy E; Krishnan, Anuradha et al. (2018) Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice. J Hepatol 69:676-686
Moncsek, Anja; Al-Suraih, Mohammed S; Trussoni, Christy E et al. (2018) Targeting senescent cholangiocytes and activated fibroblasts with B-cell lymphoma-extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2-/- ) mice. Hepatology 67:247-259
Cheung, Angela C; Lorenzo Pisarello, Maria J; LaRusso, Nicholas F (2018) Pathobiology of biliary epithelia. Biochim Biophys Acta Mol Basis Dis 1864:1220-1231
Cheung, Angela C; LaRusso, Nicholas F; Gores, Gregory J et al. (2017) Epigenetics in the Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. Semin Liver Dis 37:159-174
Loarca, Lorena; De Assuncao, Thiago M; Jalan-Sakrikar, Nidhi et al. (2017) Development and characterization of cholangioids from normal and diseased human cholangiocytes as an in vitro model to study primary sclerosing cholangitis. Lab Invest 97:1385-1396
Cheung, Angela C; Lazaridis, Konstantinos N; LaRusso, Nicholas F et al. (2017) Emerging pharmacologic therapies for primary sclerosing cholangitis. Curr Opin Gastroenterol 33:149-157
O'Hara, Steven P; Splinter, Patrick L; Trussoni, Christy E et al. (2017) ETS Proto-oncogene 1 Transcriptionally Up-regulates the Cholangiocyte Senescence-associated Protein Cyclin-dependent Kinase Inhibitor 2A. J Biol Chem 292:4833-4846
Gradilone, Sergio A; Pisarello, Maria J Lorenzo; LaRusso, Nicholas F (2017) Primary Cilia in Tumor Biology: The Primary Cilium as a Therapeutic Target in Cholangiocarcinoma. Curr Drug Targets 18:958-963
O'Hara, Steven P; La Russo, Nicholas F (2017) Cellular senescence, neuropeptides and hepatic fibrosis: Additional insights into increasing complexity. Hepatology 66:318-320
Lazaridis, Konstantinos N; LaRusso, Nicholas F (2016) Primary Sclerosing Cholangitis. N Engl J Med 375:2501-2502

Showing the most recent 10 out of 54 publications